Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Arterial Infusion Chemotherapy (HAIC) Plus Tremelimumab, Durvalumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma (HCC): a Single Center, Open Label, Single Arm, Phase II Trial

NCT05864755 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05864755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05864755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Arterial Infusion Chemotherapy (HAIC) Plus Tremelimumab, Durvalumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma (HCC): a Single Center, Open Label, Single Arm, Phase II Trial
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 20, 2023
Completion date
December 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unrescetable hepatocellular carcinoma